const _data = {
    config: {
        assets: {
            images: {
                assetsType: "images",
                assets: [
                    'loader.png',
                    'button_medium_grey.png',
                    'button_medium_yellow.png',
                    'einstein_head.png',
                    'einstein_head_1.png',
                    'einstein_head_2.png.png',
                    'FM_button_medium_grey.png',
                    'FM_button_medium_yellow.png',
                    'FM_button_short_grey.png',
                    'FM_button_short_yellow.png',
                    'FM_circle_leaf_icon.png',
                    'FM_empty_frame_MC.png',
                    'FM_highlight_strip_MC.png',
                    'FM_intro_MC.png',
                    'FM_intro_MC_2.png',
                    'FM_scroll_icon.png',
                    'FM_seal_icon_copy.png',
                    'FM_team_blue.png',
                    'FM_title_placeholder.png',
                    'framehit.png',
                    'help_exit_bg.png',
                    'numberone_icon.png',
                    'numberone_iconRight.png',
                    'QuestionBg.png',
                    'rounds_bg.png',
                    'select_team_count.jpg',
                    'verify_selection.jpg',
                    'rounds_txt_bg.png.png',
                    'splash_title.png',
                    'Team_no_color.png',
                    'teams_bg.png',
                    'teams_rounds_confirmation_bg.png',
                    'teams_txt_bg.png',
                    'timer_bg.png',
                    'Banner_Left.png',
                    'Banner_Right.png',
                    'play-button.png',
                    'pause.png',
                    'numberone_icon_reverse.png',
                    'Team_Badge_01.png',
                    'Team_Badge_02.png',
                    'Team_Badge_03.png',
                    'Team_Badge_04.png',
                    'Team_Badge_05.png',


                ]
            },
            audio: {
                assetsType: "audio",
                assets: [
                    '1maraca.mp3',
                    '1measurehiton2.mp3',
                    '1measurehiton2b.mp3',
                    '2measure.mp3',
                    '2measurehi3b.mp3',
                    '2measurehi3c.mp3',
                    '2measurehiton3.mp3',
                    '3measurehi4.mp3',
                    '3measurehit.mp3',
                    '4measurehiton5_bfornorm.mp3',
                    '4measurehiton5.mp3',
                    'bigloop.mp3',
                    'buttonclick.mp3',
                    'buttonclick2.mp3',
                    'buttonclick3.mp3',
                    'coins.mp3',
                    'Buzzer.mp3',
                    'gamemusic.mp3',
                    'guitarhit.mp3',
                    'hit2.mp3',
                    'hitphil.mp3',
                    'hornhit.mp3',
                    'hornhitbig_Copy.mp3',
                    'hornhitbig2.mp3',
                    'hornhitbig3.mp3',
                    'hornroll.mp3',
                    'hornroll2.mp3',
                    'loop2.mp3',
                    'loserhit.mp3',
                    'loserhitmix.mp3',
                    'mainloop.mp3',
                    'otherloop.mp3',
                    'philhit.mp3',
                    'quietbackgroundmusic.mp3',
                    'random.mp3',
                    'random3.mp3',
                    'scratchbutton.mp3',
                    'scratchroll2.mp3',
                    'stealbuild.mp3',
                    'stealoop.mp3'
                ]
            },
            video: {
                assetType: 'video',
                assets: [
                    'game_intro.mp4',
                    'steal_intro.mp4',
                    'conclusion.mp4'
                ]

            }
        },
        questions: [
            {
                "questionID": 100,
                "questionText": "Measuring Effects on intima-media Thickness: an Evaluation Of Rosuvastatin",
                "questionTitle": "Lost in spa-a-a-a-ce.",
                "answerText": "this is answer text",
                "options": [
                    "<span class='fontHeavy'>M</span>easuring <span class='fontHeavy'>E</span>ffects on intima-media <span class='italics'><span class='fontHeavy'>T</span>hickness:</span> an <span class='fontHeavy'>E</span>valuation Of <span class='fontHeavy'>R</span>osuvastatin"
                ],
                "answers": [0],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 110,
                "questionText": "State the name of the lead author, the name of the journal, and the year in which the METEOR trial was published.",
                "questionTitle": "We JAMA. We hope you like JAMA, too.",
                "answerText": "",
                "options": [
                    "Authored by John R. Crouse Published in the <span class='italics'>Journal of the American Medical Association (JAMA)</span> in 2007"
                ],
                "answers": [0],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 120,
                "questionText": "Describe the design of the METEOR trial.",
                "questionTitle": "Who wants to be the next DESIGN star",
                "answerText": "",
                "options": [
                    "Randomized, double-blind, placebo-controlled, parallel-group clinical trial Treatment duration: 2 years"
                ],
                "answers": [1],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 130,
                "questionText": "What were the treatment groups to which patients were randomized in the METEOR trial?",
                "questionTitle": "It was, like, so random.",
                "answerText": "",
                "options": [
                    "CRESTOR 40 mg Placebo"
                ],
                "answers": [1],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 140,
                "questionText": "What was the primary end point of the METEOR trial, and how was it measured?",
                "questionTitle": "CIMTly fabulous.",
                "answerText": "",
                "options": [
                    "Annualized rate of change in maximum CIMT for 12 carotid artery sites (near and far walls of the right and left common carotid artery, carotid bulb and internal carotid artery) Measured by B mode ultrasound"
                ],
                "answers": [0],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 150,
                "questionText": "How was safety assessed during the METEOR trial?",
                "questionTitle": "S–A–F–E–T–Y Dance.",
                "answerText": "",
                "options": [
                    "Monitoring of vital signs",
                    "Adverse event reports",
                    "Clinical laboratory data - Clinical laboratory assessments included liver function tests, creatine kinase level, creatinine level, electrolytes, fasting serum glucose, hematological measurements, and urinalysis, which were measured every 3 months. Estimated glomerular filtration rate was calculated using the Modification of Diet in Renal Disease glomerular filtration rate formula",
                    "Electrocardiograms"
                ],
                "answers": [1],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 160,
                "questionText": "What were the safety results of the METEOR trial?",
                "questionTitle": "I wanna be tol-erated.",
                "answerText": "",
                "options": [
                    "Rosuvastatin was well tolerated",
                    "Frequency of adverse events was similar between treatment groups- Commonly Reported (>3%)Treatment-Emergent Adverse Events in Safety Population of Rosuvastatin Group (n=700)",
                    "Myalgia (12.7%) • Arthralgia (10.1%)",
                    "Back pain (8.4%) • Muscle spasms (3.7%)",
                    "Diarrhea (3.4%) • Tendinitis (3.3%)- Adverse events led to 79 withdrawals (11%) from the rosuvastatin group and 22 (8%) from the placebo group",
                    "In both treatment groups, the most common treatment-emergent adverse event was myalgia Ischemic cardiovascular events were considered unrelated to treatment One death in the rosuvastatin group was due to Creutzfeld-Jakob disease and was considered unrelated to treatment"
                ],
                "answers": [1],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 170,
                "questionText": "What are the conclusions of the METEOR trial?",
                "questionTitle": "You down with low LDL-C? Yeah you know me.",
                "answerText": "",
                "options": [
                    "Rosuvastatin significantly slowed the progression of atherosclerosis as assessed by CIMT measurements Rosuvastatin lowered LDL-C concentration and raised HDL-C concentration (also correct but only if the first major conclusion has also been stated)"
                ],
                "answers": [1],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 180,
                "questionText": "What was the patient population in the METEOR trial?",
                "questionTitle": "It's a METEORite if it hits the ground.",
                "answerText": "",
                "options": [
                    "Men aged 45-70 years and women aged 55-70 years who were asymptomatic and hypercholesterolemic with a low-risk of CHD (defined as Framingham risk scores of <10% over 10 years) and subclinical evidence of atherosclerotic disease as determined by an increased CIMT ≥1.2 mm and ≤3.5 mm Lipid entry criteria: LDL-C >120 mg/dL but <160 mg/dL with 2+ risk factors and a 10-year CHD risk <10%, or an LDL-C >120 mg/dL but <190 mg/dL with no additional risk factors other than age; HDL-C <60 mg/dL; TG <500 mg/dL"
                ],
                "answers": [0],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 190,
                "questionText": "Define the acronym STELLAR.",
                "questionTitle": "A STELLAR performance.",
                "answerText": "",
                "options": [
                    "Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin"
                ],
                "answers": [0],
                "time": 0,
                "isShuffled": false
            },
            {
                "questionID": 200,
                "questionText": "State the name of the lead author of the STELLAR trial, the name of the journal, and the year in which it was published.",
                "questionTitle": "Who are you? Who, who, who, who...",
                "answerText": "",
                "options": [
                    "Authored by Peter H. Jones Published in the <i>The American Journal of Cardiology in 2003</i>"
                ],
                "answers": [0],
                "time": 0,
                "isShuffled": false
            }
        ]
    }
}

export { _data }